Jefferies raises West Pharmaceutical stock price target on HVP growth

Jefferies raised its West Pharmaceutical Services price target to $475 from $410 and maintained a Buy rating, implying about 15% upside from $412.62; GLP-1 component growth accelerated to more than 30%. West’s third-quarter 2026 adjusted EPS of $2.66 and revenue of $874.5 million topped forecasts of $2.20 and $827.1 million, and the company raised its full-year outlook. However, fourth-quarter guidance implies lower GLP-1 revenue and gross margin, and InvestingPro data describes the stock as overvalued relative to fair value.

Analysis

The market is paying for a durable high-value mix shift, but the near-term earnings path is less clean than the longer-term thesis. A sharp GLP-1-related volume and gross-margin step-down can expose operating leverage in the wrong direction; if investors have extrapolated recent growth, even a temporary trough may pressure the multiple. Oral adoption is the key substitution risk, while management’s “manageable” framing needs validation in component orders, customer forecasts and capacity utilization—not just aggregate growth. A second-order check is whether injectable demand from non-GLP-1 programs and broader customer wins can absorb capacity if GLP-1 formats shift. Competitors such as Gerresheimer and Stevanato could benefit if customers diversify suppliers, though qualification cycles may limit rapid substitution.

Over the next few weeks, the analyst upgrade and strong reported results may support sentiment, but the sharp run-up leaves limited room for a miss. Over 1–3 months, focus on actual GLP-1 volumes, HVP growth, gross-margin progression and full-year guidance delivery. Over 6–18 months, successful commissioning of finishing capacity and broader high-value customer adoption could support mix and margins; M&A is optionality, not a base-case earnings driver. The contrarian risk is that investors treat component growth as insulated from drug-format changes when the volume and margin sensitivity may arrive with a lag. Thesis weakens materially if guidance is cut, HVP growth decelerates alongside GLP-1 volumes, or added capacity fails to lift mix and margins.

Key Decisions for Investors

• Do not chase WST after the sharp rally solely on the higher target. For existing holders, consider trimming into strength or keeping exposure sized for a meaningful guidance/margin disappointment.
• Watch the next update for GLP-1 component volumes, HVP growth, gross margin, order trends and capacity utilization. Treat management’s format-shift assessment as unverified until these indicators corroborate it.
• For investors seeking exposure, prefer adding on a pullback or after evidence that the implied volume decline is contained and margins stabilize; avoid an outright short absent a guidance cut or clear deterioration in those metrics.
• Revisit the thesis if oral-format adoption accelerates, customers reduce injectable forecasts, or capacity absorption disappoints. Conversely, sustained HVP growth beyond GLP-1 and improving mix would support holding through near-term volatility.